Wells Fargo & Company Lowers Agilent Technologies (NYSE:A) Price Target to $165.00

Agilent Technologies (NYSE:A) had its price target dropped by equities researchers at Wells Fargo & Company from $175.00 to $165.00 in a research note issued to investors on Thursday,Benzinga reports. The firm presently has an “overweight” rating on the medical research company’s stock. Wells Fargo & Company‘s price objective points to a potential upside of 36.27% from the company’s current price.

Other analysts have also recently issued reports about the company. Robert W. Baird boosted their price objective on Agilent Technologies from $142.00 to $165.00 and gave the company an “outperform” rating in a research report on Tuesday, November 25th. Evercore upgraded shares of Agilent Technologies from an “in-line” rating to an “outperform” rating and upped their price objective for the stock from $155.00 to $160.00 in a research report on Monday, January 5th. Barclays dropped their target price on shares of Agilent Technologies from $165.00 to $150.00 and set an “overweight” rating on the stock in a research report on Thursday. JPMorgan Chase & Co. upped their price target on shares of Agilent Technologies from $165.00 to $180.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 25th. Finally, Morgan Stanley started coverage on Agilent Technologies in a report on Tuesday, December 2nd. They issued an “overweight” rating on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Agilent Technologies presently has a consensus rating of “Moderate Buy” and an average price target of $161.29.

Agilent Technologies Stock Performance

Shares of NYSE A opened at $121.08 on Thursday. Agilent Technologies has a 1 year low of $96.43 and a 1 year high of $160.27. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.52 and a current ratio of 1.96. The company’s fifty day moving average price is $134.67 and its 200 day moving average price is $135.91. The company has a market capitalization of $34.25 billion, a PE ratio of 26.73, a price-to-earnings-growth ratio of 3.51 and a beta of 1.30.

Agilent Technologies (NYSE:A) last posted its earnings results on Wednesday, February 25th. The medical research company reported $1.36 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.37 by ($0.01). Agilent Technologies had a return on equity of 24.95% and a net margin of 18.26%.The firm had revenue of $1.80 billion for the quarter, compared to analysts’ expectations of $1.81 billion. During the same period in the previous year, the company earned $1.31 earnings per share. The company’s revenue was up 7.0% compared to the same quarter last year. Agilent Technologies has set its FY 2026 guidance at 5.900-6.040 EPS and its Q2 2026 guidance at 1.390-1.420 EPS. On average, research analysts predict that Agilent Technologies will post 5.58 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. increased its holdings in shares of Agilent Technologies by 1.8% in the second quarter. Vanguard Group Inc. now owns 33,997,845 shares of the medical research company’s stock valued at $4,012,086,000 after purchasing an additional 589,219 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its stake in Agilent Technologies by 13.8% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 14,147,601 shares of the medical research company’s stock worth $1,925,064,000 after buying an additional 1,713,216 shares during the last quarter. State Street Corp grew its holdings in Agilent Technologies by 1.9% in the 4th quarter. State Street Corp now owns 12,681,792 shares of the medical research company’s stock valued at $1,725,611,000 after buying an additional 241,029 shares in the last quarter. Wellington Management Group LLP increased its stake in shares of Agilent Technologies by 4.8% in the 3rd quarter. Wellington Management Group LLP now owns 9,380,521 shares of the medical research company’s stock worth $1,203,990,000 after acquiring an additional 433,342 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of Agilent Technologies by 0.3% in the 4th quarter. Geode Capital Management LLC now owns 7,425,861 shares of the medical research company’s stock worth $1,006,519,000 after acquiring an additional 25,139 shares during the last quarter.

Trending Headlines about Agilent Technologies

Here are the key news stories impacting Agilent Technologies this week:

• Positive Sentiment: Management raised FY‑2026 revenue ambition to $7.3B–$7.5B and highlighted expansion of its Ignite operating system as a path to future margin improvement. Read More.
• Positive Sentiment: Most sell‑side firms remain constructive (buy/overweight) and retain multi‑quarter price targets well above the current level despite trimming targets this week — supporting medium‑term upside if growth/margins recover. Read More.
• Neutral Sentiment: Agilent issued Q2 FY2026 EPS guidance of $1.39–1.42 and FY EPS of $5.90–6.04, which sits roughly around Street expectations — guidance is not a major beat or miss. Read More.
• Neutral Sentiment: Q4/CY2025 results were reported in line with expectations earlier, so the current reaction is focused on Q1 specifics and forward execution rather than a broader trend break. Read More.
• Negative Sentiment: Q1 results narrowly missed: EPS $1.36 vs. $1.37 consensus and revenue ~$1.80B vs. ~$1.81–1.84B estimates — the miss (and a weak margin cadence) triggered a near‑term selloff in earnings reaction. Read More.
• Negative Sentiment: Management said a severe U.S. winter storm disrupted shipments and service in the quarter, pressuring near‑term revenue and gross margins — investors may see this as a risk to near‑term execution. Read More.
• Negative Sentiment: Operating profit and operating cash flow declined year‑over‑year (cash from operations down notably), which raises short‑term concerns about margin leverage and free‑cash‑flow conversion. Institutional trimming noted in recent filings adds to near‑term selling pressure. Read More.

About Agilent Technologies

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company’s product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett‑Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.